Therapeutic Potentials of Ecto-Nucleoside Triphosphate Diphosphohydrolase, Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase, Ecto-5′-Nucleotidase, and Alkaline Phosphatase Inhibitors

Medicinal Research Reviews

Volumn 34, Issue 4, 2014, Pages 703-743

  Al Rashida, Mariya ^a   Iqbal, Jamshed ^b  

^a Tobe Camp University Road Abbottabad   (Pakistan)

^b FORMAN CHRISTIAN COLLEGE A CHARTERED UNIVERSITY   (Pakistan)

Author keywords

Ecto 5 nucleotidase; Ecto nucleoside triphosphate diphosphohydrolase, ecto nucleotide pyrophosphatase phosphodiesterase, alkaline phosphatase; Ecto nucleotidase; Enzyme inhibitors

Indexed keywords

6 CHLORO 2 OXO N (4 SULFAMOYLPHENYL) 2H CHROMENE 3 CARBOXYLIC ACID AMIDE; ALKALINE PHOSPHATASE; ANTHRAQUINONE DERIVATIVE; CARBOXYLIC ACID; CHROMENE DERIVATIVE; ECTO 5' NUCLEOTIDASE; ECTO NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE; ENZYME INHIBITOR; MYRICETIN; NUCLEOSIDE; NUCLEOTIDE; NUCLEOTIDE PYROPHOSPHATASE; PHOSPHODIESTERASE; PYROPHOSPHATE; QUERCETIN; UNCLASSIFIED DRUG; 5' NUCLEOTIDASE; APYRASE; INORGANIC PYROPHOSPHATASE; POLYOXOMETALATE I; TUNGSTEN DERIVATIVE;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL PROLIFERATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; IC 50; IMMUNE RESPONSE; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM;

5'-NUCLEOTIDASE; ALKALINE PHOSPHATASE; ANIMALS; APYRASE; ENZYME INHIBITORS; HUMANS; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; TUNGSTEN COMPOUNDS;

EID: 84901850023     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21302     Document Type: Article

References (208)

1. Zimmermann H, Mishra SK, Shukla V, Langer D, Gampe K, Grimm I, Delic J, Braun N. Ecto-nucleotidases, molecular properties and functional impact. An R Acad Nac Farm 2007;73:537-566.
2. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007;87:659-797.
3. Fredholm BB, Izerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacolog y. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011;63:1-34.
4. Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal 2006;2:409-430.
5. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008;1783:673-694.
6. Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 2007;64:1471-1483.
7. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Séguéla P, Voigt M, Humphrey PP. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 2001;53:107-118.
8. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors-From molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006;58:281-341.
9. Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 2006;7:423-436.
10. Gorini S, Gatta L, Pontecorvo L, Vitiello L, la Sala A. Regulation of innate immunity by extracellular Nucleotides. Am J Blood Res 2013;3(1):14-28.
11. Kukulski F, Lévesque SA, Sévigny J. Impact of ectoenzymes on P2 and P1 receptor signaling. Adv Pharmacol 2011;61:263-299.
12. Kukulski F, Lévesque SA, Lavoie EG, Lecka J, Bigonnesse F, Knowles AF, Robson SC, Kirley TL, Sévigny J. Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 2005;1:193-204.
13. Bigonnesse F, Lévesque SA, Kukulski F, Lecka J, Robson SC, Fernandes MJ, Sévigny J. Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-8. Biochemistry 2004;43:5511-5519.
14. Lavoie EG, Kukulski F, Lévesque SA, Lecka J, Sévigny J. Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-3. Biochem Pharmacol 2004;67:1917-1926.
15. Knowles AF. The GDA1_CD39 superfamily: NTPDases with diverse functions. Purinergic Signal 2011;7:21-45.
16. 2+)-apyrase. J Biol Chem 1996;271:9898-9901.
17. Zimmermann H. Ectonucleotidases: Some recent developments and a note on nomenclature. Drug Dev Res 2001;52:44-56.
18. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362:299-309.
19. Iqbal J, Vollmayer P, Braun N, Zimmermann H, Müller CE. A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction. Purinergic Signal 2005;1:349-358.
20. Zebisch M, Strater N. Structural insight into signal conversion and inactivation by NTPDase2 in purinergic signaling. Proc Natl Acad Sci USA 2008;105:6882-6887.
21. Zebisch M, Schäfer P, Krauss M, Sträter N. Crystallographic evidence for a domain motion in rat nucleoside triphosphate diphosphohydrolase (NTPDase) 1. J Mol Biol 2012;15:288-306.
22. Krug U, Zebisch M, Krauss M, Sträter N. Structural insight into the activation mechanism of Toxoplasma gondii nucleoside triphosphate diphosphohydrolases by disulfide reduction. J Biol Chem 2012;287:3051-3066.
23. Matoba K, Shiba T, Takeuchi T, Sibley LD, Seiki M, Kikyo F, Horiuchi T, Asai T, Haradaa S. Crystallization and preliminary X-ray structural analysis of nucleoside triphosphate hydrolases from Neospora caninum and Toxoplasma gondii. Acta Crystallogr Sect F Struct Biol Cryst Commun 2010;66:1445-1448.
24. O'Keeffe MG, Thorne PR, Housley GD, Robson SC, Vlajkovic SM. Distribution of NTPDase5 and NTPDase6 and the regulation of P2Y receptor signalling in the rat cochlea. Purinergic Signal 2010;6:249-261.
25. Zebisch M, Krauss M, Schafer P, Lauble, P, Strater N. Crystallographic snapshots along the reaction pathway of nucleoside triphosphate diphosphohydrolases. Structure 2013;21:1460-1475.
26. Huitema LF, Apschner A, Logister I, Spoorendonk KM, Bussmann J, Hammond CL, Schulte-Merker S. Entpd5 is essential for skeletal mineralization and regulates phosphate homeostasis in zebrafish. Proc Natl Acad Sci USA 2012;109:21372-21377.
27. Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: Unity in diversity. Trends Biochem Sci 2005;30:542-550.
28. Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 2000;35:393-432.
29. Iqbal J, Levesque SA, Sévigny J, Müller CE. A highly sensitive CE-UV method with dynamic coating of silica-fused capillaries for monitoring of nucleotide pyrophosphatase/phosphodiesterase reactions. Electrophoresis 2008;29:3685-3693.
30. Cimpean A, Stefan C, Gijsbers R, Stalmans W, Bollen M. Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2. Biochem J 2004;381:71-77.
31. Gijsbers R, Ceulemans H, Stalmans W, Bollen M. Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases. J Biol Chem 2001;276:1361-1368.
32. Vollmayer P, Clair T, Goding JW, Sano K, Servos J, Zimmermann H. Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases. Eur J Biochem 2003;270:2971-2978.
33. Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta 2003;1638:1-19.
34. Vaingankar SM, Fitzpatrick TA, Johnson K, Goding JW, Maurice M, Terkeltaub R. Subcellular targeting and function of osteoblast nucleotide pyrophosphatase phosphodiesterase 1. Am J Physiol Cell Physiol 2004;286:C1177-C1187.
35. Dimatteo C, Marucci A, Palazzo A, Cisternino C, Marsano RM, Trischitta V, Di Paola R. Role of somatomedin-B-like domains on ENPP1 inhibition of insulin signaling. Biochim Biophys Acta 2012;1833:552-558.
36. Maddux BA, Goldfine ID. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 2000;49:13-19.
37. Chin CN, Dallas-Yang Q, Liu F, Ho T, Ellsworth K, Fischer P, Natasha T, Ireland C, Lu P, Li C, Wang IM, Strohl W, Berger JP, An Z, Zhang BB, Jiang G. Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity. Eur J Pharmacol 2009;606:17-24.
38. Rutsch F, Vaingankar S, Johnson K, Goldfine I, Maddux B, Schauerte P, Kalhoff H, Sano K, Boisvert WA, Superti-Furga A, Terkeltaub R. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001;8:543-554.
39. Johnson K, Goding J, Van Etten D, Sali A, Hu SI, Farley D, Krug H, Hessle L, Millán JL, Terkeltaub R. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003;18:994-1004.
40. Côté N, El Husseini D, Pépin A, Bouvet C, Gilbert LA, Audet A, Fournier D, Pibarot P, Moreau P, Mathieu P. Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats. Eur J Pharmacol 2012;689:139-146.
41. Kato K, Nishimasu H, Okudaira S, Mihara E, Ishitani R, Takagi J, Aoki J, Nureki O. Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling. Proc Natl Acad Sci USA 2012;109:16876-16881.
42. Kato K, Nishimasu H, Mihara E, Ishitani R, Takagi J, Aoki J, Nureki O. Expression, purification, crystallization and preliminary X-ray crystallographic analysis of Enpp1. Acta Crystallogr Sect F Struct Biol Cryst Commun 2012;68:778-782.
43. Jansen S, Perrakis A, Ulens C, Winkler C, Andries M, Joosten RP, Van Acker M, Luyten FP, Moolenaar WH, Bollen M. Structure of NPP1, an ectonucleotide pyrophosphatase/phosphodiesterase involved in tissue calcification. Structure 2012;20:1948-1959.
44. Albers HM, Ovaa H. Chemical evolution of autotaxin inhibitors. Chem Rev 2012;112:2593-2603.
45. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a Novel G proteincoupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003;278:25600-25606.
46. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-591.
47. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009;15:539-550.
48. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud OJ. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Clin Invest 2004;114:1714-1725.
49. Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S, Fells J, Uchiyama A, Murakami-Murofushi K, Kennel S, Wall J, Patil R, Gupte R, Balazs L, Miller DD, Tigyi GJ. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans 2012;40:31-36.
50. Hausmann J, Kamtekar S, Christodoulou E, Day JE, Wu T, Fulkerson Z, Albers HM, van Meeteren LA, Houben AJ, van Zeijl L, Jansen S, Andries M, Hall T, Pegg LE, Benson TE, Kasiem M, Harlos K, Kooi CW, Smyth SS, Ovaa H, Bollen M, Morris AJ, Moolenaar WH, Perrakis A. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol 2011;18:198-204.
51. Zalatan JG, Fenn TD, Brunger AT, Herschlag D. Structural and functional comparisons of nucleotide pyrophosphatase/phosphodiesterase and alkaline phosphatase: Implications for mechanism and evolution. Biochemistry 2006;45:9788-9803.
52. Hausmann J, Perrakis A, Moolenaar WH. Structure-function relationships of autotaxin, a secreted lysophospholipase D. Adv Biol Regul 2013;53:112-117.
53. Nishimasu H, Okudaira S, Hama K, Mihara E, Dohmae N, Inoue A, Ishitani R, Takagi J, Aoki J, Nureki O. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol 2011;18:205-212.
54. Nishimasu H, Ishitani R, Aoki J, Nureki O. A 3D view of autotaxin. Trends Pharmacol Sci 2012;33:138-145.
55. Koyama M, Nishimasu H, Ishitani R, Nureki O. Molecular dynamics simulation of Autotaxin: Roles of the nuclease-like domain and the glycan modification. J Phys Chem B 2012;116:11798-11808.
56. Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 2000;35:393-432.
57. Yano Y, Hayashi Y, Sano K, Shinmaru H, Kuroda Y, Yokozaki H, Yoon S, Kasuga M. Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-3 (E-NPP3/CD203c/PD-I beta/B10/gp130RB13-6) in human colon carcinoma. Int J Mol Med 2003;12:763-766.
58. Bühring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 2004;133:317-329.
59. Hennersdorf F, Florian S, Jakob A, Baumgärtner K, Sonneck K, Nordheim A, Biedermann T, Valent P, Bühring HJ. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res 2005;15:325-335.
60. Zimmermann H, Zebisch M, Sträter N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012;8:437-502.
61. Sakagami H, Aoki J, Natori Y, Nishikawa K, Kakehi Y, Natori Y, Arai H. Biochemical and molecular characterization of a novel cholinespecific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family. J Biol Chem 2005;280:23084-23093.
62. Albright RA, Chang WC, Robert D, Ornstein DL, Cao W, Liu L, Redick ME, Young JI, De La Cruz EM, Braddock DT. NPP4 is a procoagulant enzyme on the surface of vascular endothelium. Blood 2012;120:4432-4440.
63. Sidique S, Ardecky R, Su Y, Narisawa S, Brown B, Millan JL, Sergienko E, Cosford ND. Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). Bioorg Med Chem Lett 2009;19:222-225.
64. Lanier M, Sergienko E, Simao AM, Su Y, Chung T, Millan JL, Cashman JR. Design and synthesis of selective inhibitors of placental alkaline phosphatase. Bioorg Med Chem 2010;18:573-579.
65. Millan JL. Alkaline phosphatases: Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal 2006;2:335-341.
66. Langer D, Ikehara Y, Takebayashi H, Hawkes R, Zimmermann H. The ectonucleotidases alkaline phosphatase and nucleoside triphosphate diphosphohydrolase 2 are associated with subsets of progenitor cell populations in the mouse embryonic, postnatal and adult neurogenic zones. Neuroscience 2007;150:863-879.
67. Strater N. Ecto-5′-nucleotidase: Structure function relationships. Purinergic Signal 2006;2:343-350.
68. Knofel T, Strater N. Mechanism of hydrolysis of phosphate esters by the dimetal center of 5′-nucleotidase based on crystal structures. J Mol Biol 2001;309:239-254.
69. Bork P, Sander C, Valencia A. An ATPase domain common to prokaryotic cell cycle proteins, sugar kinases, actin, and hsp70 heat shock proteins. Proc Natl Acad Sci USA 1992;89:7290-7294.
70. Schuler H. ATPase activity and conformational changes in the regulation of actin. Biochim Biophys Acta 2001;1549:137-147.
71. Smith TM, Kirley TL. Site-directed mutagenesis of a human brain ecto-apyrase: Evidence that the E-type ATPases are related to the actin/heat shock 70/sugar kinase superfamily. Biochemistry 1999;38:321-328.
72. Okuhata R, Otsuka Y, Tsuchiya T, Kanzawa N. Mutagenesis of apyrase conserved region 1 alters the nucleotide substrate specificity. Plant Signal Behav 2013;8:e24131.
73. Vorhoff T, Zimmermann H, Pelletier J, Sévigny J, Braun N. Cloning and characterization of the ecto-nucleotidase NTPDase3 from rat brain: Predicted secondary structure and relation to other members of the E-NTPDase family and actin. Purinergic Signal 2005;1:259-270.
74. Grondal EJ, Zimmermann H. Purification, characterization and cellular localization of 5′-nucleotidase from Torpedo electric organ. Biochem J 1987;245:805-810.
75. Zachowski A, Evans WH, Paraf A. Immunological evidence that plasma-membrane 5′-nucleotidase is a transmembrane protein. Biochim Biophys Acta 1981;644:121-126.
76. Baron MD, Pope B, Luzio JP. The membrane topography of ecto-5′-nucleotidase in rat hepatocytes. Biochem J 1986;236:495-502.
77. Stanley KK, Edwards MR, Luzio JP. Subcellular distribution and movement of 5′-nucleotidase in rat cells. Biochem J 1980;186:59-69.
78. Farquhar MG, Bergeron JJ, Palade GE. Cytochemistry of Golgi fractions prepared from rat liver. J Cell Biol. 1974;60:8-25.
79. Little JS, Widnell CC. Evidence for the translocation of 5′-nucleotidase across hepatic membranes in vivo. Proc Natl Acad Sci USA 1975;72:4013-4017.
80. Maguire GA, Luzio JP. The presence and orientation of ecto-5′-nucleotidase in rat liver lysosomes. FEBS Lett 1985;180:122-126.
81. Pesi R, Turriani M, Allegrini S, Scolozzi C, Camici M, Ipata PL, Tozzi MG. The bifunctional cytosolic 5′-nucleotidase: Regulation of the phosphotransferase and nucleotidase activities. Arch Biochem Biophys 1994;312:75-80.
82. Walldén K, Stenmark P, Nyman T, Flodin S, Gräslund S, Loppnau P, Bianchi V, Nordlund P. Crystal structure of human cytosolic 5′-nucleotidase II: Insights into allosteric regulation and substrate recognition. J Biol Chem 2007;282:17828-17836.
83. Rinaldo-Matthis A, Rampazzo C, Reichard P, Bianchi V, Nordlund P. Crystal structure of a human mitochondrial deoxyribonucleotidase. Nat Struct Biol 2002;9:779-787.
84. Pesi R, Allegrini S, Careddu MG, Filoni DN, Camici M, Tozzi MG. Active and regulatory sites of cytosolic 5′-nucleotidase. FEBS J 2010;277:4863-4872.
85. Kawashima Y, Nagasawa T, Ninomiya H. Contribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells. Blood 2000;96: 2157-2162.
86. Misumi Y, Ogata S, Ohkubo K, Hirose S, Ikehara Y. Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form. Eur J Biochem 1990;191:563-569.
87. Resta R, Hooker SW, Hansen KR, Laurent AB, Park JL, Blackburn MR, Knudsen TB, Thompson LF. Murine ecto-5′-nucleotidase (CD73): cDNA cloning and tissue distribution. Gene 1973;133:171-177.
88. Klemens MR, Sherman WR, Holmberg NJ, Ruedi JM, Low MG, Thompson LF. Characterization of soluble vs membrane-bound human placental 5′-nucleotidase. Biochem Biophys Res Commun 1990;172:1371-1377.
89. Fini C, Talamo F, Cherri S, Coli M, Floridi A, Ferrara L, Scaloni A. Biochemical and mass spectrometric characterization of soluble ecto-5-nucleotidase from bull seminal plasma. Biochem J 2003;372:443-451.
90. Letho MT, Sharon FJ. Release of the glycosylphosphatidylinositolanchored enzyme ecto-5-nucleotidase by phospholipase C: Catalytic activation and modulation by the lipid bilayer. Biochem J 1998;332:101-109.
91. Vogel M, Kowaleski H, Zimmermann H, Hooper NM, Turner AJ. Soluble low-K. 5′-nucleotidase from electric-ray (Torpedo marmorata) electric organ and bovine cerebral cortex is derived from the glycosyl-phosphatidylinositol-anchored ectoenzyme by phospholipase C cleavage. Biochem J 1992;284:621-624.
92. Knapp K, Zebisch M, Pippel J, El-Tayeb A, Müller CE, Strater N. Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling. Structure 2012;20:2161-2173.
93. Zimmermann H. 5′-nucleotidase: Molecular and functional aspects. Biochem J 1992;285:345-365.
94. Sowa NA, Voss MK, Zylka MJ. Recombinant ecto-5′-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation. Mol Pain 2010;6:20.
95. Napieralski R, Kempkes B, Gutensohn W. Evidence for coordinated induction and repression of ecto-5′-nucleotidase (CD73) and the A2a adenosine receptor in a human B cell line. Biol Chem 2003;384:483-487.
96. Volmer JB, Thompson LF, Blackburn MR. Ecto-5′-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol 2006;176:4449-4458.
97. Schetinger MR, Morsch VM, Bonan CD, Wyse AT. NTPDase and 5′-nucleotidase activities in physiological and disease conditions: New perspectives for human health. Biofactors 2007;31:77-98.
98. El-Tayeb A, Iqbal J, Behrenswerth A, Romio M, Schneider M, Zimmermann H, Schrader J, Müller CE. Nucleoside-5′-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5′-nucleotidase. J Med Chem 2009;52:7669-7677.
99. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, Dikov MM, Feoktistov I. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 2011;187:6120-6129.
100. Fredholm BB, AP IJ, Jacobson KA, Linden J, Müller CE. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011;63:1-34.
101. Zhang B. CD73: A novel target for cancer immunotherapy. Cancer Res 2010;70:6407-6411.
102. Ujhazy P, Berleth ES, Pietkiewicz JM, Kitano H, Skaar JR, Ehrke MJ, Mihich E. Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance. Int J Cancer 1996;68:493-500.
103. Spychala J. Tumor-promoting functions of adenosine. Pharmacol Ther 2000;87:161-173.
104. Peng Z, Fernandez P, Wilder T, Yee H, Chiriboga L, Chan ES, Cronstein BN. Ecto-5′-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. Faseb J 2008;22:2263-2272.
105. Alam MS, Kurtz CC, Rowlett RM, Reuter BK, Wiznerowicz E, Das S, Linden J, Crowe SE, Ernst PB. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis 2009;199:494-504.
106. Baqi Y, Lee SY, Iqbal J, Ripphausen P, Lehr A, Scheiff AB, Zimmermann H, Bajorath J, Müller CE. Development of potent and selective inhibitors of ecto-5′-nucleotidase based on an anthraquinone scaffold. J Med Chem 2010;53:2076-2086.
107. Vivian JP, Riedmaier P, Ge H, Nours J Le, Sansom FM, Wilce MCJ, Byres E, Dias M, Schmidberger JW, Cowan PJ, d'Apice AJF, Hartland EL, Rossjohn J, Beddoe T. Crystal structure of a Legionella pneumophila ecto-triphosphate diphosphohydrolase, a structural and functional homolog of the eukaryotic NTPDases. Structure 2010;18:228-238.
108. Sansom FM, Robson SC, Hartland EL. Possible effects of microbial ecto-nucleoside triphosphate diphosphohydrolases on host-pathogen interactions. Microbiol Mol Biol R 2008;72:765-781.
109. Knofel T, Strater N. X-ray structure of the Escherichia coli periplasmic 5′-nucleotidase containing a dimetal catalytic site. Nat Struct Mol Biol 1999;6:448-453.
110. Barat C, Martin G, Beaudoin AR, Sévigny J, Tremblay MJ. The nucleoside triphosphate diphosphohydrolase-1/CD39 is incorporated into human immunodeficiency type 1 particles, where it remains biologically active. J Mol Biol 2007;371:269-282.
111. Müller CE, Iqbal J, Baqi Y, Zimmermann H, Rollich A, Stephan H. Polyoxometalates-a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. Bioorg Med Chem Lett 2006;16:5943-5947.
112. Brunschweiger A, Iqbal J, Umbach F, Scheiff AB, Munkonda MN, Sévigny J, Knowles AF, Müller CE. Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: Nucleotide mimetics derived from uridine-5′-carboxamide. J Med Chem 2008;51:4518-4528.
113. Baqi Y, Weyler S, Iqbal J, Zimmermann H, Müller CE. Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal 2009;5:91-106.
114. Gendron FP, Benrezzak O, Krugh BW, Kong Q, Weisman GA, Beaudoin AR. Purine signaling and potential new therapeutic approach: Possible outcomes of NTPDase inhibition. Curr Drug Targets 2002;3:229-245.
115. Bultmann R, Wittenburg H, Pause B, Kurz G, Nickel P, Starke K. P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Naunyn Schmiedebergs Arch Pharmacol 1996;354:498-504.
116. Chen BC, Lee CM, Lin WW. Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. Br J Pharmacol 1996;119:1628-1634.
117. Tuluc F, Bultmann R, Glanzel M, Frahm AW, Starke K. P2-receptor antagonists: IV. Blockade of P2-receptor subtypes and ecto-nucleotidases by compounds related to reactive blue 2. Naunyn Schmiedebergs Arch Pharmacol 1998;357:111-120.
118. Hoffmann K, Baqi Y, Morena MS, Glanzel M, Müller CE, von Kugelgen I. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J Pharmacol Exp Ther 2009;331:648-655.
119. Bultmann R, Pause B, Wittenburg H, Kurz G, Starke K. P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates. Naunyn Schmiedebergs Arch Pharmacol 1996; 354:481-490.
120. Munkonda MN, Kauffenstein G, Kukulski F, Levesque SA, Legendre C, Pelletier J, Lavoie EG, Lecka J, Sévigny J. Inhibition of human and mouse plasma membrane bound NTPDases by P2 receptor antagonists. Biochem Pharmacol 2007;74:1524-1534.
121. Jordheim LP, Marton Z, Rhimi M, Cros-Perrial E, Lionne C, Peyrottes S, Dumontet C, Aghajari N, Chaloin L. Identification and characterization of inhibitors of cytoplasmic 5′-nucleotidase cN-II issued from virtual screening. Biochem Pharmacol 2013;85:497-506.
122. Bultmann R, Starke K. Reactive red 2: A P2y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase. Naunyn Schmiedebergs Arch Pharmacol 1995;352:477-482.
123. Giordani RB, Weizenmann M, Rosemberg DB, De Carli GA, Bogo MR, Zuanazzi JAS, Tasca T. Trichomonas vaginalis nucleoside triphosphate diphosphohydrolase and ecto-5′-nucleotidase activities are inhibited by lycorine and candimine. Parasitol Int 2010;59:226-231.
124. Chiang WC, Knowles AF. Inhibition of human NTPDase 2 by modification of an intramembrane cysteine by p-chloromercuriphenylsulfonate and oxidative cross-linking of the transmembrane domains. Biochemistry 2008;47:8775-8785.
125. Uchino K, Matsuo T, Iwamoto M, Tonosaki Y, Fukuchi A. New 5′-nucleotidase inhibitors, NPF-86IA, NPF-86IB, NPF-86IIA, and NPF-86IIB from Areca catechu; Part I. Isolation and biological properties. Planta Med 1988;54:419-422.
126. Kavutcu M, Melzig MF. In vitro effects of selected flavonoids on the 5′-nucleotidase activity. Pharmazie 1999;54:457-459.
127. Braganhol E, Tamajusuku AS, Bernardi A, Wink MR, Battastini AM. Ecto-5′-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim Biophys Acta 2007;1770:1352-1359.
128. Ripphausen P, Freundlieb M, Brunschweiger A, Zimmermann H, Müller CE, Bajorath J. Virtual screening identifies novel sulfonamide inhibitors of ecto-5′-nucleotidase. J Med Chem 2012;55:6576-6581.
129. Raza R, Saeed A, Leka J, Sévigny J, Iqbal J. Identification of small molecule sulfonic acids as ecto-5′-nucleotidase inhibitors. Med Chem 2012;8:1133-1139.
130. Lecka J, Rana MS, Sévigny J. Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation. Br J Pharmacol 2010;161:1150-1160.
131. Wittenburg H, Bultmann R, Pause B, Ganter C, Kurz G, Starke K. P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue. Naunyn Schmiedebergs Arch Pharmacol 1996;354:491-497.
132. Garvey EP, Lowen GT, Almond MR. Nucleotide and nucleoside analogues as inhibitors of cytosolic 5′-nucleotidase I from heart. Biochemistry 1998;37:9043-9051.
133. Iqbal J, Jirovsky D, Lee SY, Zimmermann H, Müller CE. Capillary electrophoresis-based nanoscale assays for monitoring ecto-5′-nucleotidase activity and inhibition in preparations of recombinant enzyme and melanoma cell membranes. Anal Biochem 2008;373:129-140.
134. Mihaylova-Todorova ST, Todorov LD, Westfall DP. Enzyme kinetics and pharmacological characterization of nucleotidases released from the guinea pig isolated vas deferens during nerve stimulation: Evidence for a soluble ecto-nucleoside triphosphate diphosphohydrolase-like ATPase and a soluble ecto-5′-nucleotidase-like AMPase. J Pharmacol Exp Ther 2002;302:992-1001.
135. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal 2006;2:351-360.
136. Gendron FP, Halbfinger E, Fischer B, Duval M, D'Orleans-Juste P, Beaudoin AR. Novel inhibitors of nucleoside triphosphate diphosphohydrolases: Chemical synthesis and biochemical and pharmacological characterizations. J Med Chem 2000;43:2239-2247.
137. Sellers LA, Simon J, Lundahl TS, Cousens DJ, Humphrey PP, Barnard EA. Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis. J Biol Chem 2001;276:16379-16390.
138. Crack BE, Pollard CE, Beukers MW, Roberts SM, Hunt SF, Ingall AH, McKechnie KC, IJzerman AP, Leff P. Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol 1995;114:475-481.
139. Levesque SA, Lavoie EG, Lecka J, Bigonnesse F, Sévigny J. Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases. Br J Pharmacol 2007;152:141-150.
140. Lecka J, Gillerman I, Fausther M, Salem M, Munkonda MN, Brosseau JP, Cadot C, Martín-Satué M, d'Orléans-Juste P, Rousseau E, Poirier D, Künzli B, Fischer B, Sévigny J. 8-BuS-ATP derivatives as specific NTPDase1 inhibitors. Br J Pharmacol 2013;169:179-196.
141. Song YF, Tsunashima R. Recent advances on polyoxometalate-based molecular and composite materials. Chem Soc Rev 2012;41:7384-7402.
142. Wall MJ, Wigmore G, Lopatar J, Frenguelli BG, Dale N. The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition. Neuropharmacology 2008;55:1251-1258.
143. 6-) and oxovanadates: Oxometalates with many biological activities. J Inorg Biochem 2009;103:536-546.
144. Krstic D, Colovic M, Bosnjakovic-Pavlovic N, Spasojevic-De Bire A, Vasic V. Influence of decavanadate on rat synaptic plasma membrane ATPases activity. Gen Physiol Biophys 2009;28:302-308.
145. Colovic MB, Bajuk-Bogdanovic DV, Avramovic NS, Holclajtner-Antunovic ID, Bosnjakovic-Pavlovic NS, Vasic VM, Krstic DZ. Inhibition of rat synaptic membrane Na(+)/K(+)-ATPase and ecto-nucleoside triphosphate diphosphohydrolases by 12-tungstosilicic and 12-tungstophosphoric acid. Bioorg Med Chem 2011;19:7063-7069.
146. Hayward S. Structural principles governing domain motions in proteins. Proteins 1999;36:425-435.
147. Zebisch M, Strater N. Characterization of Rat NTPDase1, -2, and -3 ectodomains refolded from bacterial inclusion bodies. Biochemistry 2007;46:11945-11956.
148. Fini C, Palmerini CA, Damiani P, Stochaj U, Mannherz HG, Floridi A. 5′-nucleotidase from bull seminal plasma, chicken gizzard and snake venom is a zinc metalloprotein. Biochim Biophys Acta 1990;1038:18-22.
149. Dvorak HF, Heppel LA. Metallo-enzymes released from Escherichia coli by osmotic shock. II. Evidence that 5′-nucleotidase and cyclic phosphodiesterase are zinc metalloenzymes. J Biol Chem 1968;243:2647-2653.
150. McMillen L, Beacham IR, Burns DM. Cobalt activation of Escherichia coli 5′-nucleotidase is due to zinc ion displacement at only one of two metal-ion-binding sites. Biochem J 2003;372:625-630.
151. Kummer U, Mysliwietz J, Gutensohn W, Buschette S, Jahn H, Neuser D, Munker R. Development and Properties of a Monoclonal Antibody Specific for Human Ecto-5′-Nucleotidase. Immunobiol 1984;166:203-211.
152. Smith TM, Kirley TL. Cloning, sequencing, and expression of a human brain ecto-apyrase related to both the ecto-ATPases and CD39 ecto-apyrases. Biochim Biophys Acta 1998;1386:65-78.
153. Ivanenkov VV, Meller J, Kirley TL. Characterization of disulfide bonds in human nucleoside triphosphate diphosphohydrolase 3 (NTPDase3): Implications for NTPDase structural modeling. Biochemistry 2005;44:8998-9012.
154. Vekaria RM, Shirley DG, Sévigny J, Unwin RJ. Immunolocalization of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol 2006;290:F550-F560.
155. Martín-Satué M, Lavoie EG, Pelletier J, Fausther M, Csizmadia E, Guckelberger O, Robson SC, Sévigny J. Localization of plasma membrane bound NTPDases in the murine reproductive tract. Histochem Cell Biol. 2009;131:615-628.
156. Belcher SM, Zsarnovszky A, Crawford AR, Hemani H, Spurling L, Kirley TL. Immunolocalization of ectonucleoside triphosphate diphosphohydrolase 3 in rat brain: Implication for modulation of multiple homeostatic systems including feeding and sleep-wake behaviors. Neuroscience 2005;137:1331-1346.
157. Munkonda MN, Pelletier J, Ivanenkov VV, Fausther M, Tremblay A, Künzli B, Kirley TL, Sévigny J. Characterization of a monoclonal antibody as the first specific inhibitor of human NTP diphosphohydrolase-3: Partial characterization of the inhibitory epitope and potential applications. FEBS J 2009;276:479-496.
158. Ivanenkov VV, Crawford PA, Toyama A, Sévigny J, Kirley TL. Epitope mapping in cell surface proteins by site-directed masking: Defining the structural elements of NTPDase 3 inhibition by a monoclonal antibody. Protein Eng Des Sel 2010;23:579-588.
159. Porcino GN, Carvalho-Campos C, Maia AC, Detoni ML, Faria-Pinto P, Coimbra ES, Marques MJ, Juliano MA, Juliano L, Diniz VÁ, Corte-Real S, Vasconcelos EG. Leishmania (Viannia) braziliensis nucleoside triphosphate diphosphohydrolase (NTPDase 1): Localization and in vitro inhibition of promastigotes growth by polyclonal antibodies. Exp Parasitol 2012;132:293-299.
160. Maia AC, Porcino GN, Detoni Mde L, Emídio NB, Marconato DG, Faria-Pinto P, Fessel MR, Reis AB, Juliano L, Juliano MA, Marques MJ, Vasconcelos EG. An antigenic domain within a catalytically active Leishmania infantum nucleoside triphosphate diphosphohydrolase (NTPDase 1) is a target of inhibitory antibodies. Parasitol Int 2013;62:44-52.
161. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998;19:271-273.
162. Johnson KA, Hessle L, Vaingankar S, Wennberg C, Mauro S, Narisawa S, Goding JW, Sano K, Millan JL, Terkeltaub R. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 2000;279:R1365-R1377.
163. Johnson K, Hashimoto S, Lotz M, Pritzker K, Goding J, Terkeltaub R. Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification. Arthritis Rheum 2001;44:1071-1081.
164. Gijsbers R, Aoki J, Arai H, Bollen M. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett 2003;538:60-64.
165. Jankowski M, Piwkowska A, Rogacka D, Audzeyenka I, Janaszak-Jasiecka A, Angielski S. Expression of membrane-bound NPP-type ecto-phosphodiesterases in rat podocytes cultured at normal and high glucose concentrations. Biochem Biophys Res Commun 2011;416:64-69.
166. Sortica DA, Crispim D, Zaffari GP, Friedman R, Canani LH. The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy. Arq Bras Endocrinol Metabol 2011;55:677-685.
167. Aerts I, Martin JJ, De Deyn PP, Van Ginniken C, Van Ostade X, Kockx M, Dua G, Slegers H. The expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (E-NPP1) is correlated with astrocytic tumor grade. Clin Neurol Neurosurg 2011;113:224-229.
168. David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Gres S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clezardin P, Peyruchaud O. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010;5:e9741.
169. Parrill AL, Baker DL. Autotaxin inhibition: Challenges and progress toward novel anti-cancer agents. Anticancer Agents Med Chem 2008;8:917-923.
170. van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH. Anticancer activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett 2008;266:203-208.
171. Hoeglund AB, Bostic HE, Howard AL, Wanjala IW, Best MD, Baker DL, Parrill AL. Optimization of a pipemidic acid autotaxin inhibitor. J Med Chem 2010;53:1056-1066.
172. Savaskan NE, Rocha L, Kotter MR, Baer A, Lubec G, van Meeteren LA, Kishi Y, Aoki J, Moolenaar WH, Nitsch R, Brauer AU. Autotaxin (NPP-2) in the brain: Cell type-specific expression and regulation during development and after neurotrauma. Cell Mol Life Sci 2007;64:230-243.
173. Hoeglund AB, Howard AL, Wanjala IW, Pham TC, Parrill AL, Baker DL. Characterization of non-lipid autotaxin inhibitors. Bioorg Med Chem 2010;18:769-776.
174. Clair T, Koh E, Ptaszynska M, Bandle R, Liotta L, Schiffmann E, Stracke M. L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotoxin. Lipids Health Dis 2005;4:5.
175. Cui P, McCalmont WF, Tomsig JL, Lynch KR, Macdonald TL. Alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg Med Chem 2008;16:2212-2225.
176. Xu Y, Tanaka M, Arai H, Aoki J, Prestwich GD. Alkyl lysophosphatidic acid and fluoromethylene phosphonate analogs as metabolically-stabilized agonists for LPA receptors. Bioorg Med Chem Lett 2004;14:5323-5328.
177. Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K, van Meeteren LA, Moolenaar WH, Wilke N, Siess W, Tigyi G, Miller DD. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 2005;48:4919-4930.
178. Rucker B, Almeida ME, Libermann TA, Zerbini LF, Wink MR, Sarkis JJ. Biochemical characterization of ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP, E.C. 3.1.4.1) from rat heart left ventricle. Mol Cell Biochem 2007;306:247-254.
179. Choudhary MI, Fatima N, Khan KM, Jalil S, Iqbal S,. New biscoumarin derivatives-cytotoxicity and enzyme inhibitory activities. Bioorg Med Chem 2006;14:8066-8072.
180. Choudhary MI, Fatima N, Abbasi MA, Jalil S, Ahmad VU, Atta-ur-Rahman. Phenolic glyscosides, a new class of human recombinant nucleotide pyrophosphatase phosphodiesterase-1 inhibitors. Bioorg Med Chem 2004;12:5793-5798.
181. Khan KM, Fatima N, Rasheed M, Jalil S, Ambreen N, Perveen S, Choudhary MI. 1, 3, 4-Oxadiazole-2(3H) thione and its analogues: A new class of non-competitive nucleotide pyrophosphatases/phosphodiesterases 1 inhibitors. Bioorg Med Chem 2009;17:7816-7822.
182. Eliahu S, Lecka J, Reiser G, Haas M, Bigonnesse F, Levesque SA, Pelletier J, Sévigny J, Fischer B. Diadenosine 5′, 5′′-(boranated)polyphosphonate analogues as selective nucleotide pyrophosphatase/phosphodiesterase inhibitors. J Med Chem 2010;53:8485-8497.
183. Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 2007;282:15872-15883.
184. Kaunitz JD, Yamaguchi DT. TNAP, TrAP, ecto-purinergic signaling, and bone remodeling. J Cell Biochem 2008;105:655-662.
185. Li L, Chang L, Pellet-Rostaing S, Liger F, Lemaire M, Buchet R, Wu Y. Synthesis and evaluation of benzo[b]thiophene derivatives as inhibitors of alkaline phosphatases. Bioorg Med Chem 2009;17:7290-7300.
186. Kozlenkov A, Le Du MH, Cuniasse P, Ny T, Hoylaerts MF, Millan JL. Residues determining the binding specificity of uncompetitive inhibitors to tissue-nonspecific alkaline phosphatase. J Bone Miner Res 2004;19:1862-1872.
187. Chang L, Duy DL, Mébarek S, Popowycz F, Pellet-Rostaing S, Lemaire M, Buchet R. Synthesis and evaluation of thiophenyl derivatives as inhibitors of alkaline phosphatase. Bioorg Med Chem Lett 2011;21:2297-2301.
188. Sergienko E, Su Y, Chan X, Brown B, Hurder A, Narisawa S, Millan JL. Identification and characterization of novel tissue-nonspecific alkaline phosphatase inhibitors with diverse modes of action. J Biomol Screen. 2009;14:824-837.
189. Shirazi SP, Beechey RB, Butterworth PJ. The use of potent inhibitors of alkaline phosphatase to investigate the role of the enzyme in intestinal transport of inorganic phosphate. Biochem J 1981;194:803-809.
190. Holtz KM, Stec B, Kantrowitz ER. A model of the transition state in the alkaline phosphatase reaction. J Biol Chem 1999;274:8351-8354.
191. Gazzarrini C, Stagni N, Pollesello P, D'Andrea P, De Bernard B. Possible mechanism of inhibition of cartilage alkaline phosphatase by insulin. Latina Acta Diabetol Lat 1989;26:32-37.
192. Thompson KH, Orvig C. Design of vanadium compounds as insulin-enhancing agents. J Chem Soc Dalton Trans 2000;2885-2892.
193. Ferrer EG, Salinas MV, Correa MJ, Vrdoljak F, Williams PAM. ALP inhibitors: Vanadyl(IV) complexes of ferulic and cinnamic acid. Z Naturforsch 2005;60b:305-311.
194. Hazarika P, Kalita D, Sarmah S, Islam NS. New oxo-bridged peroxotungsten complexes containing biogenic co-ligand as potent inhibitors of alkaline phosphatase activity. Mol Cell Biochem 2006;284:39-47.
195. Hazarika P, Kalita D, Islam NS. Mononuclear and dinuclear peroxotungsten complexes with co-ordinated dipeptides as potent inhibitors of alkaline phosphatase activity. J Enzyme Inhib Med Chem 2008;23:504-513.
196. Hazarika P, Sarmah S, Kalita D, Islam NS. New peroxovanadium compounds containing biogenic co-ligands: Synthesis, stability and effect on alkaline phosphatase activity. Transition Met Chem 2008;33:69-77.
197. Raza R, Matin A, Sarwar S, Barsukova-Stuckart M, Ibrahim M, Kortz U, Iqbal J. Polyoxometalates as potent and selective inhibitors of alkaline phosphatases with profound anticancer and amoebicidal activities. Dalton Trans 2012;41:14329-14336.
198. Price GH. Sulfonamide inhibition of human alkaline phosphatase. Clin Chim Acta 1979;94:211-217.
199. Price GH. Inhibition of alkaline phosphatase by several diuretics. Clin Chim Acta 1980;101:313-319.
200. Dahl R, Sergienko EA, Su Y, Mostofi YS, Yang L, Simao AM, Narisawa S, Brown B, Mangravita-Novo A, Vicchiarelli M, Smith LH, O'Neill WC, Millán JL, Cosford ND. Discovery and validation of a series of aryl sulfonamides as selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). J Med Chem 2009;52:6919-6925.
201. al-Rashida M, Raza R, Abbas G, Shah MS, Kostakis GE, Lecka J, Sévigny J, Muddassar M, Papatriantafyllopoulou C, Iqbal J. Identification of novel chromone based sulfonamides as highly potent and selective inhibitors of alkaline phosphatases. Eur J Med Chem 2013;66:438-449.
202. al-Rashida M, Ashraf M, Hussain B, Nagra SA, Abbas G. Discovery of new chromone containing sulfonamides as potent inhibitors of bovine cytosolic carbonic anhydrase. Bioorg Med Chem 2011;19:3367-3371.
203. Minai-Tehrani D, Khodai S, Aminnaseri S, Minoui S, Sobhani-Damavadifar Z, Alavi S, Osmani R, Ahmadi S. Inhibition of renal alkaline phosphatase by cimetidine. Drug Metab Lett 2011;5:197-201.
204. Vovk AI, Kalchenko VI, Cherenok SA, Kukhar VP, Muzychka OV, Lozynsky MO. Calix[4]arene methylenebisphosphonic acids as calf intestine alkaline phosphatase inhibitors. Org Biomol Chem 2004;2:3162-3166.
205. Vovk AI, Chuííko AL, Kononets LA, Tanchuk VIu, Murav'eva IV, Lozinskií MO, Kukhar VP. Inhibition of alkaline phosphatase by thioureido derivatives of methylenebisphosphonic acid. Bioorg Khim 2008;34:67-74.
206. Meštrović V, Pavela-Vrančič M. Inhibition of alkaline phosphatase activity by okadaic acid, a protein phosphatase inhibitor. Biochimie 2003;85:647-650.
207. Chakraborty S, Asgeirsson B, Minda R, Salaye L, Frère JM, Rao BJ. Inhibition of a cold-active alkaline phosphatase by imipenem revealed by in silico modeling of metallo-β-lactamase active sites. FEBS Lett 2012;586:3710-3715.
208. Khan I, Hanif M, Hussain MT, Khan AA, Aslam MAS, Rama NH, Iqbal J. Synthesis, acetylcholinesterase and alkaline phosphatase inhibition of some new 1, 2, 4-Triazole and 1, 3, 4-Thiadiazole derivatives. Aust J Chem 2012;65:1413-1419.